Nausea, vomiting, diarrhoea and constipation may occur, particularly at higher doses or during dose increases as the body adjusts to treatment
If air bubbles are present, tap the syringe gently and push the air out before redrawing the dose if needed
Semaglutide is generally discussed as a GLP-1 receptor agonist model, Tirzepatide as a dual GIP and GLP-1 receptor agonist model, and Retatrutide as a triple receptor agonist model involving GLP-1, GIP, and glucagon receptor pathways
GLP-1 Case Study Name: Richard J., a 58-year-old male Medical History: Type 2 Diabetes Mellitus (diagnosed 7 years ago) Obesity (BMI 35 kg/m) Hypertension (well-controlled on an ACE inhibitor) Mild diabetic retinopathy Current Medications: Metformin 1000 mg twice daily, glimepiride 2 mg once daily, and lisinopril 20 mg once daily Clinical Presentation Richard presents a routine follow-up
Keeping your gut balanced may increase the production of substances like SCFAs that boost GLP-1
Withdrawal symptoms can also occur when individuals stop taking GLP-1 medications: Reduced side effects: While semaglutide or tirzepatide can lead to side effects like acid reflux, nausea, constipation and abdominal pain, stopping the medication can reduce these side effects